Monte Rosa Therapeutics, Inc.
GLUE- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001826457
In the last 90 days, Monte Rosa Therapeutics, Inc. insiders filed 0 open-market purchases and 3 sales; 192 institutions reported holding it in 13F filings for Q2 2026, worth $2.24B in total; Duquesne Family Office is the only superinvestor holding it.
13F holders, Q1 2026
Institutional positions in Monte Rosa Therapeutics, Inc. as of Mar 31, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 191
- +32 vs. Q4 2025
- Shares held
- 87.0M
- +25.7M (+42.0%) vs. Q4 2025
- Total value
- $1.43B
- +$470.2M (+49.0%) vs. Q4 2025
- New holders
- 52
- 84 more added
- Sold out
- 20
- 41 more reduced
2 institutions that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting GLUE on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 192 | $2.24B |
| Q1 2026 | 191 | $1.43B |
| Q4 2025 | 161 | $1.01B |
| Q3 2025 | 129 | $444.9M |
| Q2 2025 | 116 | $280.6M |
| Q1 2025 | 106 | $276.2M |
| Q4 2024 | 105 | $423.3M |
| Q3 2024 | 81 | $263.7M |
| Q2 2024 | 75 | $171.7M |
| Q1 2024 | 68 | $281.3M |
| Q4 2023 | 71 | $226.6M |
| Q3 2023 | 71 | $201.4M |
| Q2 2023 | 68 | $272.3M |
| Q1 2023 | 69 | $309.8M |
| Q4 2022 | 66 | $313.8M |
| Q3 2022 | 70 | $328.8M |
| Q2 2022 | 57 | $375.0M |
| Q1 2022 | 52 | $559.9M |
| Q4 2021 | 53 | $742.0M |
| Q3 2021 | 56 | $759.4M |
| Q2 2021 | 48 | $705.1M |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2026
Shares, value and share of portfolio for each institution holding Monte Rosa Therapeutics, Inc.; share changes are against Q4 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Brevan Howard Capital Management LP | 0 | $0 | 0.00% | −13,323−100.0% | Sold out |
| Gsa Capital Partners LLP | 0 | $0 | 0.00% | −12,981−100.0% | Sold out |
| Pallas Capital Advisors LLC | 0 | $0 | 0.00% | −11,320−100.0% | Sold out |
| Baader Bank INC | 0 | $0 | 0.00% | −11,000−100.0% | Sold out |
| Amalgamated Bank | 0 | $0 | 0.00% | −1,465−100.0% | Sold out |
| Spire Wealth Management | 0 | $0 | 0.00% | −509−100.0% | Sold out |
| Daiwa Securities Group Inc. | 0 | $0 | 0.00% | −203−100.0% | Sold out |
| Bessemer Group Inc | 0 | $0 | 0.00% | −34−100.0% | Sold out |
| Caitong International Asset Management Co., Ltd | 0 | $0 | 0.00% | −27−100.0% | Sold out |
| Turning Point Benefit Group, Inc. | 0 | $0 | 0.00% | −14−100.0% | Sold out |
| Clearstead Advisors, LLC | 0 | $0 | 0.00% | −8−100.0% | Sold out |
| Vanguard Group Inc | – | – | – | – | Not filed |
| Comerica Bank | – | – | – | – | Not filed |